





Two-year use of flash glucose monitoring is associated with sustained improvement of glycemic control and quality of life (FLARE-NL-6)

Annel Lameijer ¹, Marion J Fokkert ², Mireille A Edens ³,
Reinold O B Gans,⁴ Henk J G Bilo,⁵ Peter R van Dijk ¹

To cite: Lameijer A, Fokkert MJ, Edens MA, *et al*. Two-year use of flash glucose monitoring is associated with sustained improvement of glycemic control and quality of life (FLARE-NL-6). *BMJ Open Diab Res Care* 2021;**9**:e002124. doi:10.1136/bmjdr-2021-002124

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjdr-2021-002124>).

Received 9 January 2021
Accepted 18 August 2021



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to
Dr Annel Lameijer;
a.lameijer@umcg.nl

ABSTRACT

Introduction The FreeStyle Libre (FSL) is a flash glucose monitoring (FGM) system. The Flash Monitor Register in the Netherlands (FLARE-NL-4) study previously demonstrated the positive effects of FSL-FGM use during 1 year on glycemic control, quality of life and disease burden among persons with diabetes mellitus (DM). The present follow-up study assesses the effects of FSL-FGM after 2 years.

Research design and methods Patients included in the FLARE-NL-4 study who continued FSL-FGM during the 1-year study period were invited to participate (n=687). Data were collected using questionnaires (the 12-item Short Form Health Survey version 2 (SF-12^{v2}) and the EuroQol 5-Dimension 3-Level (EQ-5D-3L) for quality of life), including self-reported hemoglobin A1c (HbA1c).

Results A total of 342 patients agreed to participate: mean age 48.0 (±15.6) years, 52% men and 79.5% with type 1 DM. HbA1c decreased from 60.7 (95% CI 59.1 to 62.3) mmol/mol before use of FSL-FGM to 57.3 (95% CI 55.8 to 58.8) mmol/mol after 1 year and 57.8 (95% CI 56.0 to 59.5) mmol/mol after 2 years. At the end of the 2-year follow-up period, 260 (76%) persons were still using the FSL-FGM and 82 (24%) had stopped. The main reason for stopping FSL-FGM was financial constraints (55%). Concerning the whole 2-year period, there was a significant decrease in HbA1c among persons who continued use of FSL-FGM (−3.5 mmol/mol, 95% CI −6.4 to −0.7), while HbA1c was unaltered compared with baseline among persons who stopped FSL-FGM (−2.4 mmol/mol, 95% CI −7.5 to 2.7): difference between groups 2.2 (95% CI −1.3 to 5.8) mmol/mol. After 2 years, persons who continued use of FSL-FGM had higher SF-12 mental component score and higher EQ-5D Dutch tariff score and felt less often anxious or depressed compared with persons who discontinued FSL-FGM.

Conclusions Although the considerable number of non-responders limits generalizability, this study suggests that persons who continue to use FSL-FGM for 2 years may experience sustained improvement in glycemic control and quality of life.

INTRODUCTION

During the last decades real-time continuous glucose measurement (rt-CGM) has been introduced to measure glucose

SIGNIFICANCE OF THIS STUDY

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT?

⇒ Use of FreeStyle Libre flash glucose monitoring (FSL-FGM) system is often associated with (short-term) improved glycemic control and quality of life.

WHAT ARE THE NEW FINDINGS?

⇒ This study demonstrates that use of FSL-FGM for 2 years is associated with sustained improvement in (self-reported) hemoglobin A1c.
⇒ Persons who continued use of FSL-FGM for at least 2 years experience improvements in quality of life as compared with persons who stopped FSL-FGM use.
⇒ In this study, financial constraints were the main reason for stopping FSL-FGM.

HOW MIGHT THESE RESULTS CHANGE THE FOCUS OF RESEARCH OR CLINICAL PRACTICE?

⇒ This study is one of the first to emphasize the valuable impact of FSL-FGM use in clinical practice over a longer period of time.

concentrations in the interstitial fluid. Flash glucose monitoring is a variant of rt-CGM in which the user obtains results intermittently by using a reader. In 2014, Freestyle Libre flash glucose monitoring (FSL-FGM, Abbott) was introduced. In contrast to most CGM devices, the FSL-FGM is already factory-calibrated with no need for daily calibration. Compared with fingerprick testing, FSL-FGM readings can be performed painless after insertion and provide additional information on trends in glucose levels during day and night.

In order to acquire evidence on the effects, efficacy and safety of use of FSL-FGM in the Netherlands, a nationwide registry ('FLash monitor REgistry - NetherLands FLARE-NL') was established in 2016.¹ The FLARE-NL-4 study demonstrated a decrease

in hemoglobin A1c (HbA1c) (from 64 to 60 mmol/mol) over a 1-year study period and, importantly, improved the quality of life, decreasing rates of work absenteeism and fewer diabetes-related hospital admissions.¹ These results were confirmed by other studies that also demonstrated improved glycemic control and quality of life.²⁻⁶ However, most of these studies are hampered by a limited study period (often <1 year).

In order to provide insight into the long-term use of FSL-FGM, the results of 2-year follow-up measurements among persons who participated in the FLARE-NL-4 study are described in the current study. Next to glycemic control, outcomes concerning quality of life and disease burden are presented.

METHODS

Study design, patient selection and aims

The FLARE-NL-4 register study had a prospective, observational design. Detailed information concerning the FLARE-NL registry and the 1-year outcomes have been published earlier.¹⁷ The present study aims to describe the effects of FSL-FGM at 2-year follow-up. We invited patients who participated in the 1-year FLARE-NL-4 study (n=1365) who had continued to use FSL-FGM for a minimum of 1 year (n=687). Invitations to participants were sent by email. A total of 342 patients agreed to participate in this 2-year follow-up study.

Outcomes

The primary outcome was glycemic control over the 2-year study period. Furthermore, changes in health-related quality of life and disease burden were investigated and comparisons were made between persons who continued use of FSL-FGM for at least 2 years and persons who stopped FSL-FGM before the 2-year follow-up was completed. Additionally, data were analyzed for persons with type 1 and type 2 diabetes mellitus (DM) separately.

Study procedures

After informed consent was obtained, study participants received a link to report their most recent HbA1c values and to fill out the online questionnaires regarding glycemic control, quality of life and disease burden. Glycemic control was assessed using self-reported most recent HbA1c values and the number of self-reported clinically significant hypoglycemia (defined as a glucose <3 mmol/L⁸) in the past 6 months, measured with FSL-FGM or finger-prick testing. Additionally, participants were asked if they had experienced any hypoglycemic event during the past 6 months. Quality of life in the previous year was assessed by the EuroQol 5-Dimension 3-Level (EQ-5D-3L) questionnaire and the 12-Item Short Form Health Survey version 2 (SF-12^{v2}). The EuroQol is a generic measure developed by researchers from five European countries, including the Netherlands.⁹

The EQ-5D-3L is one of the most widely used instruments for measuring health-related quality of life.¹⁰ This questionnaire consists of two parts. The first is a descriptive system which comprises the following five dimensions: mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Each dimension has three levels: no problems, some problems and extreme problems. The second is the EQ-5D Visual Analogue Scale from which a single overall score for self-rated health status can be elicited, ranging from 0 to 100.^{10 11} The EQ-5D Dutch tariff is a valuation of all possible EQ-5D-3L health states, based on estimated regression coefficients. This score ranges from 0 to 1, where 1 refers to full health and 0 refers to death.¹² The SF-12 questionnaire measures eight health dimensions, among others general health, limitations in physical activities due to health problems, social functioning and vitality (energy/fatigue). The Physical Component Summary (PCS) and the Mental Component Summary (MCS) are two subscales derived from the SF-12.¹³ To investigate disease burden, the number of hospitalizations related to DM in the previous year and work absenteeism rate in the previous 6 months were measured using the questionnaire. In the FLARE-NL-4 study we strived for a more value-based healthcare approach. As such, the study also focused on patient-reported outcome measures (PROMs), using a list compiled in collaboration with the Dutch Diabetes Patient Association (Diabetes Vereniging Nederland; DVN) to assess the degree of disease burden experienced by the study population in relation to their DM and the usefulness of FSL-FGM. This questionnaire has been described in more detail previously and the questions as asked in the DVN-PROM can be found in the supplemental material attached to the FLARE-NL-4 paper.¹

Statistical analyses

Categorical data were expressed as n (%). To determine if variables were normally distributed, Q-Q plots and histograms were used. Normally distributed data were expressed as mean±SD and skewed distributed data as median with IQR. The Fisher's exact test was used to analyze categorical variables. The Mann-Whitney U test was used to compare continuous variables if the data were distributed skewed. Linear mixed models with Bonferroni corrections were used to calculate estimated values (with 95% CI) and to test for differences between the three moments in time (t=0, t=1 and t=2 years) and between groups. In the model the fixed factors continued and stopped FSL-FGM were used as determinants. The difference in scores was determined based on the b-coefficient of each particular (continued or stopped FSL-FGM use) group. Significance of the b-coefficient was investigated with the Wald test based on p<0.05. The quantity of the b-coefficient, with 95% CI, gives the

Table 1 Baseline characteristics

	All (N=342)	Continued FSL-FGM (n=260)	Stopped FSL-FGM (n=82)
Male gender, n (%)	178 (52.0)	140 (53.8)	38 (46.3)
Age, years	48.0 (15.6)	47.7 (15.8)	49.0 (15.1)
HbA1c, mmol/mol	61.2 (12.9)	62.1 (13.3)	58.2 (11.4)*
HbA1c, %	7.8 (1.2)	7.8 (1.2)	7.5 (1.0)*
Type of diabetes, n (%)			
Type 1 diabetes	272 (79.5)	214 (82.3)	58 (70.7)
Type 2 diabetes	45 (13.2)	30 (11.5)	15 (18.3)
Latent autoimmune diabetes in adults (LADA)	16 (4.7)	10 (3.8)	6 (7.3)
Maturity-onset diabetes of the young (MODY)	2 (0.6)	1 (0.4)	1 (1.2)
Other forms of diabetes	7 (2.0)	5 (1.9)	2 (2.4)
Complications, n (%)			
Microvascular complications	121 (35.4)	89 (34.2)	32 (39.0)
Neuropathy	71 (20.8)†	52 (20.0)	19 (23.2)
Albuminuria	62 (18.1)	47 (18.1)	15 (18.3)
Retinopathy	72 (21.1)	50 (19.2)	22 (26.8)
Macrovascular complications	50 (14.6)	38 (14.6)	12 (14.6)
Data are presented as number (%) or mean (SD). *P<0.05. †Data available for 108 persons (80 persons who continued and 28 who stopped FSL-FGM). FSL-FGM, FreeStyle Libre flash glucose monitoring; HbA1c, hemoglobin A1c.			

difference between both treatment modalities over the study period adjusted for baseline differences. Statistical analyses were performed using SPSS V.26.0. A significance level of 5% (two-sided) was used.

RESULTS

A total of 342 persons of the invited 687 (49.8%) agreed to participate in this follow-up study. As presented in table 1, 178 (52.0%) of the participants were men, with a mean age of 48.0 (\pm 15.6) years and the majority of the population (79.5%) with type 1 DM.

Changes over time among all participants are presented in table 2. HbA1c decreased significantly from 60.7 (95% CI 59.1 to 62.3) mmol/mol before use of FSL-FGM to 57.3 (95% CI 55.8 to 58.8) mmol/mol after 1 year and 57.8 (95% CI 56.0 to 59.5) after 2 years.

Concerning quality of life, the SF-12 PCS increased during the study period. The number of working days lost and the hospital admission rate were not different as compared with baseline (table 2).

After 2 years, 260 (76.0%) persons were still using FSL-FGM and 82 (24.0%) had stopped before the 2-year follow-up was completed. Financial constraints (54.9%) and termination of the FLARE-NL-4 study (13.4%) were

the main reasons for stopping FSL-FGM (table 3). Besides a higher baseline HbA1c among persons who continued FSL-FGM, there were no significant differences between groups at baseline. Among persons who continued FSL-FGM, 114 (43.8%) had reimbursement of the FSL-FGM by their healthcare insurance and 146 (56.2%) paid for the FSL-FGM themselves.

Changes over time among persons who continued and stopped FSL-FGM use are presented in table 4. HbA1c decreased significantly over the whole 2-year study period among persons who continued FSL-FGM (mean difference -3.5 mmol/mol, 95% CI -6.4 to -0.7), while this was -2.4 mmol/mol (95% CI -7.5 to 2.7) mmol/mol for persons who stopped FSL-FGM. The overall difference between groups was 2.2 (95% CI -1.3 to 5.8) mmol/mol.

The number of hypoglycemic events was not different after 2 years of follow-up in both groups. At 2 years, the percentage of persons who reported at least one hypoglycemic event during the past 6 months was higher in the continued versus the group that stopped FSL-FGM use (88.5% vs 79.3%, $p<0.05$; online supplemental table 4).

The SF-12 MCS remained stable among persons who continued FSL-FGM use over the 2-year period. Over the whole study period, the difference in SF-12 MCS change, as well as the difference in change of the EQ-5D Dutch tariff score, was significantly better among persons who continued FSL-FGM use as compared with persons who stopped (difference: 5.0 (95% CI 2.7 to 7.3) and 0.07 (95% CI 0.02 to 0.1), respectively). The SF-12 PCS increased in both groups. After 2 years, the percentage of persons who reported work absenteeism and hospital admission was lower for persons who continued FSL-FGM as compared with persons who stopped FSL-FGM (5.0% vs 14.6% ($p<0.01$) and 5.4% vs 12.2% ($p<0.05$), respectively, presented in online supplemental table 4).

Online supplemental table 2 and 3 show the effects of use of FSL-FGM on changes in glycemic control, quality of life and disease burden for persons with type 1 DM ($n=272$) and type 2 DM ($n=45$) separately. The significant changes described above concerning HbA1c, SF-12 PCS, SF-12 MCS and EQ-5D Dutch tariff score among persons who continued FSL-FGM were also observed among persons with type 1 DM who continued FSL-FGM.

As presented in online supplemental table 5, when comparing the outcomes of the DVN-PROM questionnaire after 2 years of follow-up between persons who continued and persons who stopped FSL-FGM, persons who continued FSL-FGM reported their hypoglycemic episodes were less severe (81.9% vs 11.4%), performed more adjustments of insulin dose (81.9% vs 30.4%), had a better understanding of glucose fluctuations (94.5% vs 7.6%), more often measured their glucose levels prior to traffic participation (65.4% vs 39.2%) and participated more frequently in sports activities (42.9% vs 3.8%). Importantly, persons who used the FSL-FGM felt more secure (77.2% vs 8.9%). Furthermore, people with whom they live together were less concerned about the glucose regulation of their partner (65.0% vs 9.0%).

Table 2 Changes in glycemic control, quality of life and disease burden among all participants

	Baseline (A)	1 year (B)	2 years (C)	B vs A	C vs A	C vs B
Glycemia						
HbA1c	60.7 (59.1 to 62.3)	57.3 (55.8 to 58.8)	57.8 (56.0 to 59.5)	-3.4 (-6.1 to -0.7)	-2.9 (-5.9 to -0.02)	0.5 (-2.4 to 3.3)
n	341	253	342			
Hypoglycemic events in the past 6 months	64.7 (55.3 to 74.0)	66.3 (55.0 to 77.6)	51.0 (42.1 to 59.9)	1.6 (-16.2 to 19.5)	-13.6 (-29.4 to 2.1)	-15.3 (-32.8 to 2.3)
n	325	311	294			
Quality of life						
EQ-5D-3L Dutch tariff	0.8 (0.8 to 0.9)	0.9 (0.8 to 0.9)	0.8 (0.8 to 0.9)	0.01 (-0.03 to 0.05)	0.0 (-0.04 to 0.04)	-0.01 (-0.05 to 0.03)
n	342	342	336			
EQ-VAS	69.8 (67.4 to 72.2)	71.7 (69.0 to 74.4)	73.9 (71.0 to 76.9)	1.9 (-2.5 to 6.3)	4.1 (-0.5 to 8.7)	2.2 (-2.6 to 7.1)
n	342	342	336			
SF-12 ^{v2} PCS score	38.2 (37.4 to 38.9)	47.2 (46.2 to 48.2)	46.9 (45.9 to 47.9)	9.1 (7.6 to 10.6)	8.7 (7.2 to 10.2)	-0.4 (-2.1 to 1.4)
n	342	342	342			
SF-12 ^{v2} MCS score	48.8 (47.6 to 50.1)	49.4 (48.3 to 50.5)	47.5 (46.4 to 48.7)	0.6 (-1.5 to 2.6)	-1.3 (-3.4 to 0.8)	-1.9 (-3.8 to 0.03)
n	342	333	333			
Disease burden						
Hospital admissions	0.1 (0.04 to 0.2)	0.1 (-0.01 to 0.1)	1.3 (-2.2 to 4.8)	-0.1 (-0.2 to 0.1)	1.2 (-3.1 to 5.5)	1.3 (-3.0 to 5.6)
n	342	342	341			
Lost working days	6.0 (2.7 to 9.3)	5.1 (2.2 to 8.0)	5.7 (1.5 to 9.9)	-0.9 (-6.3 to 4.5)	-0.3 (-6.8 to 5.6)	0.6 (-5.6 to 6.8)
n	342	342	339			

Data are presented as mean (difference) with 95% CI.
HbA1c concentrations are presented in mmol/mol.
EQ-5D-3L, three-level version of EuroQol 5 Dimension; EQ-VAS, EQ-Visual Analogue Scale; HbA1c, hemoglobin A1c; MCS, Mental Component Summary; PCS, Physical Component Summary; SF-12^{v2}, 12-Item Short Form Health Survey version 2.

DISCUSSION

In the present study we describe follow-up data concerning FSL-FGM derived from a nationwide registry. HbA1c decreased significantly after 2 years of follow-up. Among persons who continued FSL-FGM during the whole 2-year period, there was HbA1c reduction of -3.5 mmol/mol (95% CI -6.4 to -0.7), while HbA1c remained unchanged among persons who stopped FSL-FGM. Importantly, we observed significant (sustained) improvements in readouts of quality of life (SF-12 MCS, EQ-5D Dutch tariff score, and levels of anxiety and depression) among persons who continued FSL-FGM compared with persons who stopped.

Table 3 Reasons for discontinuing FSL-FGM

Reason for stopping FSL-FGM	n (%)
Financial constraints	45 (54.9)
End of the study	11 (13.4)
Unsatisfied with ease of use	3 (3.7)
Allergy to the adhesives	3 (3.7)
Use of an alternative to FSL-FGM	3 (3.7)
Inadequate glucose regulation despite FSL-FGM	1 (1.2)
FSL-FSG is regarded unreliable	1 (1.2)
Undefined	15 (18.3)
Total	82 (100)

FSL-FGM, FreeStyle Libre flash glucose monitoring.

The observed association between HbA1c improvement and FSL-FGM use is in line with recent publications.^{1 2 5 14-16} The current study adds by demonstrating a significant HbA1c improvement over a 2-year period among FSL-FGM users. We were unable to demonstrate a difference in change of HbA1c over the 2-year study period between persons who continued FSL-FGM and those who stopped before the 2-year follow-up was completed. We hypothesize that this is related to the fact that the group of persons who stopped FSL-FGM had already used FSL-FGM for at least 1 year, which likely has provided them with more insight into their glucose regulation (and fluctuations).¹⁴ We expect this 'learning effect' to have a positive influence on glycemic control during the following months after discontinuation of FSL-FGM.

The number of reported hypoglycemic events after 2 years of FSL-FGM use was not different as compared with baseline. However, the percentage of persons who detected at least one episode of hypoglycemia was higher among FSL-FGM users compared with persons who stopped. Importantly, in the DVN-PROM questionnaire, FSL-FGM users reported their hypoglycemic episodes to be less severe. Charleer *et al*¹⁵ found a higher number of perceived hypoglycemic episodes among FSL-FGM users as compared with the period when they used self-monitoring of blood glucose (SMBG), possibly related to more detailed insight into glucose fluctuations

Table 4 Changes in glycaemic control, quality of life and disease burden among persons who continued FSL-FGM for at least 2 years and persons who had stopped FSL-FGM before the 2-year follow-up period was completed

	Baseline (A)			1 year (B)			2 years (C)			C vs A			C vs B			Overall difference between groups
	Continued FSL-FGM	Stopped FSL-FGM	n	Continued FSL-FGM	Stopped FSL-FGM	n	Continued FSL-FGM	Stopped FSL-FGM	n	Continued FSL-FGM	Stopped FSL-FGM	n	Continued FSL-FGM	Stopped FSL-FGM	n	
Glycemia																
HbA1c	62.4 (60.8 to 64.0)	59.0 (56.2 to 61.8)	259	58.3 (56.8 to 59.7)	56.4 (53.8 to 58.9)	260	58.9 (57.2 to 60.6)	56.7 (53.6 to 59.8)	82	3.5 (-6.4 to -0.7)	-2.4 (-7.5 to 2.7)	0.6 (-2.1 to 3.4)	0.3 (-4.6 to 5.2)	2.2 (-1.3 to 5.8)		
n	259	82	191	260	82	260	260	82	82							
Hypoglycaemic events	61.8 (52.8 to 70.8)	67.5 (51.1 to 83.9)	250	60.3 (49.7 to 70.9)	72.3 (52.4 to 92.2)	242	51.3 (43.0 to 59.7)	50.7 (35.0 to 66.4)	65	-10.5 (-25.4 to 4.5)	-16.8 (-44.5 to 10.9)	-9.0 (-25.5 to 7.5)	-21.6 (-52.5 to 9.4)	0.6 (-17.2 to 18.4)		
n	250	75	242	260	69	229	260	65	65							
Quality of life																
EQ-VAS	70.9 (69.5 to 74.2)	67.7 (63.6 to 71.9)	260	73.8 (71.2 to 76.4)	69.6 (64.9 to 74.2)	260	74.8 (71.9 to 77.6)	74.8 (71.9 to 77.6)	80	2.9 (-1.7 to 7.4)	5.3 (-2.8 to 13.4)	0.9 (-3.8 to 5.7)	3.5 (-5.0 to 12.0)	1.7 (-4.2 to 7.6)		
n	260	82	260	260	82	260	260	80	80							
EQ-5D-3L Dutch tariff	0.85 (0.83 to 0.87)	0.84 (0.80 to 0.88)	260	0.87 (0.85 to 0.90)	0.84 (0.80 to 0.88)	260	0.88 (0.85 to 0.90)	0.81 (0.77 to 0.85)	80	0.02 (-0.02 to 0.06)	-0.03 (-0.04 to 0.04)	0.002 (-0.04 to 0.04)	-0.03 (-0.1 to 0.04)	0.07 (0.02 to 0.1)		
n	260	82	260	260	82	260	260	80	80							
SF-12 ^{v2} PCS score	37.6 (36.9 to 38.3)	38.7 (37.5 to 40.0)	260	47.4 (46.4 to 48.4)	47.1 (45.3 to 48.8)	260	47.2 (46.2 to 48.2)	46.5 (44.8 to 48.3)	82	9.6 (8.1 to 11.0)	7.8 (5.2 to 11.5)	-0.2 (-1.9 to 1.5)	-0.5 (-3.5 to 2.5)	0.7 (-1.4 to 2.7)		
n	260	82	260	260	82	260	260	82	82							
SF-12 ^{v2} MCS score	50.1 (48.8 to 51.3)	47.6 (45.4 to 49.9)	260	51.1 (50.0 to 52.1)	47.8 (45.9 to 49.6)	260	50.0 (48.9 to 51.1)	45.0 (43.1 to 47.0)	82	-0.03 (-2.1 to 2.0)	-2.6 (-6.2 to 1.1)	-1.1 (-2.9 to 0.8)	-2.7 (-6.1 to 0.6)	5.0 (2.7 to 7.3)		
n	260	82	254	260	79	254	260	79	79							
Disease burden																
Hospital admissions	0.1 (0.07 to 0.2)	0.1 (-0.04 to 0.2)	260	0.1 (0.03 to 0.2)	0.02 (-1.0 to 0.1)	260	2.1 (-1.4 to 5.5)	0.6 (-5.5 to 6.7)	82	1.9 (-2.3 to 6.1)	0.5 (-7.0 to 8.0)	2.0 (-2.2 to 6.2)	0.6 (-6.9 to 8.1)	2.1 (-1.4 to 5.5)		
n	260	82	260	260	82	259	260	82	82							
Lost working days	4.9 (1.6 to 8.1)	7.2 (1.4 to 13.0)	260	2.2 (-0.7 to 5.0)	8.0 (3.0 to 13.1)	260	3.4 (-0.7 to 7.5)	8.0 (3.0 to 13.1)	82	-1.5 (-7.9 to 4.9)	0.9 (-10.5 to 12.2)	1.2 (-4.9 to 7.3)	0.01 (-10.8 to 10.8)	-4.6 (-13.0 to 3.7)		
n	260	82	260	260	82	257	260	82	82							

Data are presented as mean (difference) with 95% CI.

HbA1c concentrations are presented in mmol/mol.

 EQ-5D-3L, three-level version of EuroQol 5-Dimension; EQ-VAS, EQ-Visual Analogue Scale; FSL-FGM, FreeStyle Libre flash glucose monitoring; HbA1c, hemoglobin A1c; MCS, Mental Component Summary; PCS, Physical Component Summary; SF-12^{v2}, 12-Item Short Form Health Survey version 2.

with FSL-FGM and a reduction of self-reported severe hypoglycemia.

Overall, continuing FSL-FGM was associated with improved quality of life, as compared with patients stopping FSL-FGM. Other studies have highlighted the positive influence of FSL-FGM on quality of life among persons with DM.^{4–6 15–19} Overend *et al*¹⁷ reported a positive impact of FSL-FGM on psychological well-being and self-esteem as patients with type 1 DM experienced more control over their blood glucose values. The authors attributed a reduction in frequency, severity and fear of hypoglycemia as the key positive impact on well-being. In line with these observations, the current study showed an improvement in understanding of glucose fluctuations among FSL-FGM users, and possibly related to this enhancement they felt more secure. The positive impact of FSL-FGM on quality of life is also supported by the results of the EQ-5D-3L questionnaire: among patients who continued use of FSL-FGM for 2 years, the reported level of anxiety and depression was significantly lower compared with patients who stopped FSL-FGM (online supplemental table 3).

In the FLARE-NL-4 study a decrease in work absenteeism rate (within 6 months) and in annual diabetes-related hospital admission rate was observed. Previous studies also showed a decrease in diabetes-related work absenteeism and hospital admissions after initiation of FSL-FGM.^{5 15} The current follow-up study showed that stopping FSL-FGM was associated with a deterioration in the percentage of persons who reported work absenteeism and diabetes-related hospital admissions, compared with persons who continued FSL-FGM.

Of note, during the 1-year FLARE-NL-4 study, patients had to finance half of the cost of the FSL-FGM themselves if they did not fulfill the Dutch criteria for FSL-FGM reimbursement, and during the second year of use this group (56% of persons) had to pay the full amount (approximately €120 per month) themselves. This study demonstrated that 24% of persons stopped FSL-FGM use after the first year. For these persons financial constraints were the main reason for stopping.

This study has several limitations. Data were obtained from a nationwide registry and follow-up questionnaires and as such lacked a comparator. As discussed, a considerable number of persons included in the original FLARE-NL-4 study did not participate in the present follow-up study, potentially resulting in selection bias. Importantly, in this study we did not have access to FSL-FGM data; therefore, information concerning glucose metrics such as time in range is not available. Furthermore, information about the frequency of glucose monitoring, known to be associated with better glycemic control,²⁰ was not included in the database. As data were patient-reported, recall bias may be present. The exact time point when participants stopped using FSL-FGM is unknown.

Since the majority of participants had to finance the costs of the FSL-FGM themselves after 1 year, this inevitably will contribute to selection bias, since the actual participants

probably will be more affluent than the average DM population, which may be related to a higher quality of life among FSL-FGM users. Patients used FSL-FGM for several indications, as described in the FLARE-NL-4 study.¹

Finally, it should be mentioned that one of the questionnaires (the 'DVN-PROM') used in this study has not been validated yet. Although the DVN-PROM was non-validated, we still find the results valuable and useful as they represent the results of a collaboration with a DM patient organization and FSL-FGM users and the questions asked are very recognizable for both caregivers and patients.

CONCLUSION

Although a considerable number of persons from the original FLARE-NL-4 study were unavailable for this follow-up study, the data suggest that FSL-FGM use by persons with DM for a 2-year period was associated with sustained improvement of self-reported HbA1c compared with the period before FSL-FGM use. Aspects of experienced quality of life were higher among persons who continued FSL-FGM as compared with persons who discontinued FSL-FGM before the 2-year follow-up period was completed. Financial motives were the main reason for discontinuing FSL-FGM.

Author affiliations

¹University of Groningen, University Medical Center Groningen, Department of Endocrinology, Groningen, The Netherlands

²Department of Clinical Chemistry, Isala, Zwolle, The Netherlands

³Department of Innovation and Science, Isala, Zwolle, The Netherlands

⁴University of Groningen, University Medical Center Groningen, Department of Internal Medicine, Groningen, The Netherlands

⁵Diabetes Research Center, Isala, Zwolle, The Netherlands

Acknowledgements We thank all the participants for allowing us to use their data for the study and Jeanette Braakman for data collection.

Contributors AL: statistical analysis, interpretation of data, writing of the manuscript. MJF: collection of data, critical review of the manuscript. MAE: interpretation of data, critical review of the manuscript. ROBG: critical review of the manuscript. HJGB: design, critical review of the manuscript. PRVD: design, statistical analysis, interpretation of data, critical review of the manuscript. All authors approved the final version of the manuscript.

Funding The FLARE-NL registry was funded by an unconditional grant (number Z699) from Stichting Achmea Gezondheidszorg (SAG). The SAG is an innovation fund of the health insurance company Zilverenkruis. The manufacturer of the FreeStyle Libre (Abbott) did not provide any finances for the proposed study and did not have any influence on study design nor on the definition of the target groups or the study objectives.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The study protocol was approved by the Medical Ethical Committee of Isala (Zwolle, The Netherlands) (METC 16.0346).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Data are available via the corresponding author upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines,

terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Annel Lameijer <http://orcid.org/0000-0003-2407-3370>

Marion J Fokkert <http://orcid.org/0000-0002-4687-1157>

Mireille A Edens <http://orcid.org/0000-0001-5449-5035>

Peter R van Dijk <http://orcid.org/0000-0002-9702-6551>

REFERENCES

- Fokkert M, van Dijk P, Edens M, *et al*. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). *BMJ Open Diabetes Res Care* 2019;7:e000809.
- Castellana M, Parisi C, Di Molfetta S, *et al*. Efficacy and safety of flash glucose monitoring in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis. *BMJ Open Diabetes Res Care* 2020;8:e001092.
- Mancini G, Berlioli MG, Santi E, *et al*. Flash glucose monitoring: a review of the literature with a special focus on type 1 diabetes. *Nutrients* 2018;10. doi:10.3390/nu10080992. [Epub ahead of print: 29 Jul 2018].
- Rouhard S, Buyschaert M, Alexopoulou O, *et al*. Impact of flash glucose monitoring on glycaemic control and quality of life in patients with type 1 diabetes: a 18-month follow-up in real life. *Diabetes Metab Syndr* 2020;14:65–9.
- Deshmukh H, Wilmot EG, Gregory R, *et al*. Effect of flash glucose monitoring on glycaemic control, hypoglycemia, diabetes-related distress, and resource utilization in the association of British clinical diabetologists (ABCD) nationwide audit. *Diabetes Care* 2020;43:dc200738.
- Ang E, Lee ZX, Moore S, *et al*. Flash glucose monitoring (FGM): a clinical review on glycaemic outcomes and impact on quality of life. *J Diabetes Complications* 2020;34:107559.
- Fokkert MJ, Damman A, van Dijk PR, *et al*. Use of freestyle libre flash monitor register in the Netherlands (FLARE-NL1): patient experiences, satisfaction, and cost analysis. *Int J Endocrinol* 2019;2019:1–6.
- International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American diabetes association and the European association for the study of diabetes. *Diabetes Care* 2017;40:155–7.
- EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. *Health Policy* 1990;16:199–208.
- Van Reenen M, Janssen B. *EQ-5D-3L user guide: basic information on how to use the EQ-5D-3L instrument*. Rotterdam, Netherlands: EuroQol Research Foundation, 2015.
- Lammers LM, Stalmeijer PFM, McDonnell J. "Kwaliteit van leven meten in economische evaluaties: het Nederlands EQ-5D-tarief,". *Nederlands Tijdschrift Voor Geneeskunde* 2005;149:1574–8 <https://www.ntvg.nl/artikelen/kwaliteit-van-leven-meten-economische-evaluaties-het-nederlands-eq-5d-tarief/artikelinfo>
- Lamers LM, Stalmeier PFM, McDonnell J, *et al*. [Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff]. *Ned Tijdschr Geneesk* 2005;149:1574–8.
- Ware J, Kosinski M, Keller SD. A 12-Item short-form health survey: construction of scales and preliminary tests of reliability and validity. *Med Care* 1996;34:220–33.
- Evans M, Welsh Z, Ells S, *et al*. The impact of flash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analysis of clinical trials and real-world observational studies. *Diabetes Ther* 2020;11:83–95.
- Charleer S, De Block C, Van Huffel L, *et al*. Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently Scanned continuous glucose monitoring in adults living with type 1 diabetes (future): a prospective observational real-world cohort study. *Diabetes Care* 2020;43:389–97.
- Tyndall V, Stimson RH, Zammitt NN, *et al*. Marked improvement in HbA_{1c} following commencement of flash glucose monitoring in people with type 1 diabetes. *Diabetologia* 2019;62:1349–56.
- Overend L, Simpson E, Grimwood T. Qualitative analysis of patient responses to the ABCD freestyle libre audit questionnaire. *Pract Diab* 2019;36:45–50.
- Kramer G, Michalak L, Müller UA, *et al*. Association between flash glucose monitoring and metabolic control as well as treatment satisfaction in outpatients with diabetes type 1. *Exp Clin Endocrinol Diabetes* 2021;129:303–8.
- Al Hayek AA, Al Dawish MA. The potential impact of the freestyle libre flash glucose monitoring system on mental well-being and treatment satisfaction in patients with type 1 diabetes: a prospective study. *Diabetes Ther* 2019;10:1239–48.
- Lameijer A, Lommerde N, Dunn TC, *et al*. Flash glucose monitoring in the Netherlands: increased monitoring frequency is associated with improvement of glycaemic parameters. *Diabetes Res Clin Pract* 2021;177:108897.

Supplements

Supplementary Table 1. Changes in glycaemic control, quality of life and disease burden among persons with type 1 DM who continued FSL-FGM for at least two years and persons who had stopped FSL-FGM before the two-year follow-up period was completed

	Baseline (A)		One year (B)		Two years (C)		C vs. A		C vs. B		Overall difference between groups
	Continued FSL-FGM	Stopped FSL-FGM	Continued FSL-FGM	Stopped FSL-FGM	Continued FSL-FGM	Stopped FSL-FGM	Continued FSL-FGM	Stopped FSL-FGM	Continued FSL-FGM	Stopped FSL-FGM	
Glycemia											
HbA1c	62.5 (60.8, 64.2)	58.9 (55.7, 62.2)	58.5 (57.0, 60.1)	56.0 (53.1, 59.0)	58.7 (56.8, 60.6)	57.3 (53.6, 60.9)	-3.8 (-6.9, -0.7)	-1.7 (-7.6, 4.2)	0.1 (-2.8, 3.0)	1.2 (-4.5, 6.9)	1.4 (-2.7, 5.5)
N	213	58	156	43	214	58					
Hypoglycemic events	66.1 (56.0, 76.3)	73.0 (53.6, 92.4)	60.5 (49.0, 72.0)	85.5 (63.0, 108.0)	52.7 (43.3, 62.2)	52.4 (33.8, 71.1)	-13.4 (-30.3, 3.5)	-20.6 (-53.4, 12.2)	-7.8 (-25.9, 10.4)	-33.1 (-68.7, 2.6)	0.3 (-20.6, 21.2)
N	208	57	202	53	190	49					
Quality of life											
EQ-5D-3L VAS	72.7 (70.3, 75.1)	70.4 (65.8, 75.0)	73.6 (70.7, 76.6)	70.8 (65.2, 76.5)	75.6 (72.4, 78.8)	72.0 (65.9, 78.2)	2.9 (-2.0, 7.7)	1.6 (-7.7, 11.0)	2.0 (-3.3, 7.3)	1.2 (-9.0, 11.4)	3.6 (-3.3, 10.5)
N	214	58	214	58	211	56					
EQ-5D Dutch tariff	0.85 (0.83, 0.88)	0.84 (0.80, 0.89)	0.88 (0.86, 0.90)	0.86 (0.81, 0.90)	0.88 (0.86, 0.91)	0.83 (0.79, 0.88)	0.03 (-0.01, 0.07)	-0.01 (-0.1, 0.1)	0.0 (-0.04, 0.04)	-0.02 (-0.1, 0.1)	0.05 (0.0, 0.1)
N	214	58	214	58	211	56					
SF-12 ^{v2} PCS	37.8 (37.0, 38.6)	39.8 (38.2, 41.3)	48.0 (47.0, 49.0)	48.3 (46.3, 50.3)	47.7 (46.7, 48.8)	47.1 (45.0, 49.1)	9.9 (8.3, 11.5)	7.3 (4.2, 10.4)	-0.3 (-2.1, 1.6)	-1.2 (-4.7, 2.3)	0.69 (-1.6, 3.0)
N	214	58	214	58	214	58					
SF-12 ^{v2} MCS	50.2 (48.8, 51.6)	45.7 (43.0, 48.3)	51.4 (50.2, 52.5)	47.9 (45.6, 50.1)	50.2 (49.0, 51.4)	44.4 (42.0, 46.7)	0.0 (-2.2, 2.3)	-1.3 (-5.6, 3.1)	-1.1 (-3.2, 0.9)	-3.5 (-7.5, 0.5)	5.8 (3.2, 8.5)
N	214	58	209	55	209	55					
Disease burden											
Hospital admissions	0.1 (0.1, 0.2)	0.1 (-0.1, 0.2)	0.1 (-0.001, 0.1)	0.03 (-0.08, 0.2)	2.5 (-1.8, 6.7)	0.2 (-8.0, 8.3)	2.4 (-2.8, 7.6)	0.1 (-9.9, 10.1)	2.4 (-2.8, 7.6)	0.1 (-9.8, 10.1)	2.3 (-6.9, 11.5)
N	214	58	214	58	213	58					
Lost working days	4.5 (1.2, 7.9)	5.9 (-0.6, 12.4)	1.6 (-1.6, 4.7)	11.3 (5.2, 17.4)	4.1 (-0.9, 9.2)	11.2 (1.5, 20.9)	-0.4 (-7.8, 7.0)	5.2 (-9.0, 19.5)	2.5 (-4.7, 9.8)	-0.1 (-14.1, 13.8)	-7.1 (-18.0, 3.9)
N	214	58	214	58	211	58					

Data are presented as mean (difference) with 95% confidence interval. HbA1c concentrations are presented in mmol/mol. Abbreviations: EQ-5D-3L, 3-level version of EuroQol 5D; EQ-VAS, EQ-visual analogue scale; MCS, Mental Component Score; PCS, Physical Component Score; SF-12^{v2}, 12-Item Short Form Health Survey^{v2}.

Supplementary Table 2. Changes in glycemic control, quality of life and disease burden among persons with type 2 DM who continued FSL-FGM for at least two years and persons who had stopped FSL-FGM before the two-year follow-up period was completed

	Baseline (A)		One year (B)		Two years (C)		C vs. A		C vs. B		Overall difference between groups
	Continued FSL-FGM	Stopped FSL-FGM	Continued FSL-FGM	Stopped FSL-FGM	Continued FSL-FGM	Stopped FSL-FGM	Continued FSL-FGM	Stopped FSL-FGM	Continued FSL-FGM	Stopped FSL-FGM	
Glycemia											
HbA1c	65.2 (59.7, 70.6)	62.5 (54.8, 70.1)	59.4 (53.7, 65.1)	62.7 (54.1, 71.3)	62.6 (56.8, 68.5)	52.9 (44.7, 61.1)	-2.5 (-12.1, 7.1)	-9.6 (-23.2, 4.0)	3.3 (-6.6, 13.1)	-9.8 (-24.2, 4.6)	9.7 (-0.3, 19.8)
N	30	15	23	10	30	15					
Hypoglycemic events	27.5 (15.3, 39.6)	36.3 (15.7, 57.0)	37.2 (26.2, 48.3)	22.1 (3.0, 41.2)	45.6 (18.9, 72.4)	40.1 (-7.2, 87.4)	18.1 (-17.8, 54.0)	3.8 (-59.3, 66.9)	8.4 (-27.0, 43.9)	18.0 (-44.5, 80.5)	5.5 (-48.8, 59.9)
N	26	9	27	9	25	8					
Quality of life											
EQ-5D-3L VAS	67.4 (59.8, 75.0)	64.4 (53.6, 75.1)	72.3 (64.1, 80.5)	61.1 (49.5, 72.3)	66.5 (58.9, 75.2)	72.2 (59.9, 84.5)	-0.9 (-14.8, 13.1)	7.8 (-11.9, 27.5)	-5.7 (-20.2, 8.7)	11.1 (-9.4, 31.5)	-5.7 (-20.7, 9.4)
N	30	15	30	15	30	15					
EQ-5D Dutch tariff	0.79 (-.72, 0.86)	0.77 (0.67, 0.87)	0.78 (0.68, 0.87)	0.72 (0.59, 0.85)	0.77 (0.69, 0.89)	0.69 (0.54, 0.83)	-0.01 (-0.2, 0.1)	-0.08 (-0.3, 0.1)	0.01 (-0.2, 0.2)	-0.03 (-0.3, 0.2)	0.1 (-0.07, 0.27)
N	30	15	30	15	30	15					
SF-12 ^{v2} PCS	36.0 (34.0, 38.0)	35.7 (32.8, 38.5)	42.1 (38.8, 45.5)	41.1 (36.4, 45.8)	43.5 (39.2, 47.8)	41.2 (38.2, 44.3)	5.2 (0.8, 9.7)	7.9 (1.6, 14.1)	-0.9 (-6.4, 4.6)	2.5 (-5.3, 10.2)	-2.3 (-7.5, 3.0)
N	30	15	30	15	30	15					
SF-12 ^{v2} MCS	47.9 (44.1, 51.5)	51.2 (46.0, 56.)	49.4 (46.3, 52.5)	48.1 (43.7, 52.5)	48.8 (45.1, 52.5)	46.8 (41.6, 52.0)	0.9 (-5.4, 7.3)	-4.4 (-13.4, 4.5)	-0.5 (-6.4, 5.3)	-1.3 (-9.6, 7.0)	2.0 (-4.4, 8.4)
N	30	15	30	15	30	15					
Disease burden											
Hospital admissions	0.1 (-0.02, 0.3)	0.0 (-0.2, 0.2)	0.3 (-0.03, 0.7)	0.0 (-0.5, 0.5)	0.2 (-1.3, 1.7)	2.5 (0.4, 4.6)	0.07 (-1.8, 1.9)	2.5 (-0.1, 5.2)	-0.1 (-2.0, 1.8)	2.5 (-0.1, 5.2)	-2.3 (-4.9, 0.3)
N	30	15	30	15	30	15					
Lost working days	9.4 (-1.8, 20.6)	4.1 (-11.8, 19.9)	1.4 (-0.8, 3.6)	0.3 (-2.8, 3.3)	0.0 (-0.5, 0.5)	0.7 (-0.1, 1.4)	-9.4 (-23.3, 4.4)	-3.4 (-23.0, 16.2)	-1.4 (-4.1, 1.3)	0.4 (-3.5, 4.3)	0.7 (-0.3, 1.6)
N	30	15	30	15	30	15					

Data are presented as mean (difference) with 95% confidence interval. HbA1c concentrations are presented in mmol/mol. Abbreviations: EQ-5D-3L, 3-level version of EuroQol 5D; EQ-VAS, EQ-visual analogue scale; MCS, Mental Component Score; PCS, Physical Component Score; SF-12^{v2}, 12-Item Short Form Health Survey^{v2}.

Supplementary Table 3. EQ-5D-3L scores among persons who continued FSL-FGM for at least two years or had stopped before the two-year follow-up period was completed

	Baseline			Two years		
	All (n=342)	Continued FSL-FGM (n=260)	Stopped FSL-FGM (n=82)	All (n=331)	Continued FSL-FGM (n=253)	Stopped FSL-FGM (n=78)
Mobility						
No problems in walking about, n (%)	277 (81.0)	210 (80.8)	67 (81.7)	262 (79.2)	201 (79.4)	61 (78.2)
Some problems in walking about, n (%)	64 (18.7)	49 (18.8)	15 (18.3)	66 (19.9)	49 (19.4)	17 (21.8)
Confined to bed, n (%)	1 (0.3)	1 (0.4)	0 (0.0)	3 (0.9)	3 (1.2)	0 (0.0)
Self-care						
No problems with self-care, n (%)	328 (95.9)	249 (95.8)	79 (96.3)	320 (96.7)	246 (97.2)	74 (94.9)
Some problems with washing or dressing, n (%)	12 (3.5)	9 (3.5)	3 (3.7)	8 (2.4)	5 (2.0)	3 (3.8)
Unable to wash or dress myself, n (%)	2 (0.6)	2 (0.8)	0 (0.0)	3 (0.9)	2 (0.8)	1 (1.3)
Usual activities						
No problems with performing usual activities, n (%)	225 (65.8)	175 (67.3)	50 (61.0)	234 (70.7)	180 (71.5)	54 (69.2)
Some problems with performing usual activities, n (%)	115 (33.6)	84 (32.3)	31 (37.8)	95 (28.7)	72 (28.7)	23 (29.5)
Unable to perform usual activities, n (%)	2 (0.6)	1 (0.4)	1 (1.2)	2 (0.6)	1 (0.4)	1 (1.3)
Pain / discomfort						
No pain or discomfort, n (%)	206 (60.2)	159 (61.2)	47 (57.3)	202 (61.0)	161 (63.6)	41 (52.6)
Moderate pain or discomfort, n (%)	127 (37.1)	94 (36.2)	33 (40.2)	118 (35.6)	85 (33.6)	33 (42.3)
Extreme pain or discomfort, n (%)	9 (2.6)	7 (2.7)	2 (2.4)	11 (3.3)	7 (2.8)	4 (5.1)
Anxiety / depression						
Not anxious or depressed, n (%)	252 (73.7)	196 (75.4)	56 (68.3)	254 (76.7)	208 (82.2)	46 (59.0)
Moderately anxious or depressed, n (%)	86 (25.1)	61 (23.5)	25 (30.5)	75 (22.7)	44 (17.4)	31 (39.7)*
Extremely anxious or depressed, n (%)	4 (1.2)	3 (1.2)	1 (1.2)	2 (0.6)	1 (0.4)	1 (1.3)

Data are presented as number (%). Abbreviations: IQR, Interquartile Range. Significant outcome presented in bold. * $p < 0.001$ as compared to persons who continued FSL-FGM.

Supplementary Table 4. Changes in the percentage of persons who reported hypoglycemic events, hospital admissions and lost working days among persons who continued FSL-FGM for at least two years and persons who had stopped FSL-FGM before the two-year follow-up period was completed

	Baseline		One year		Two years	
	Continued FSL-FGM (n=260)	Stopped FSL-FGM (n=82)	Continued FSL-FGM (n=260)	Stopped FSL-FGM (n=82)	Continued FSL-FGM (n=260)	Stopped FSL-FGM (n=82)
Glycemia						
Presence of any hypoglycemic event past 6 months, yes, n (%)	250 (96.2)	75 (91.5)	242 (93.1)	69 (84.1)*	230 (88.5)	65 (79.3)*
Disease burden						
Hospital admission past 12 months, yes, n (%)	21 (8.1)	6 (7.3)	11 (4.2)	2 (2.4)	14 (5.4)	10 (12.2)*
Work absenteeism past 6 months, yes, n (%)	39 (15.0)	16 (19.5)	11 (4.2)	8 (9.8)	13 (5.0)	12 (14.6)**

Data are presented as number (%). Significant outcomes presented in bold. * $p < 0.05$ as compared to persons who continued FSL-FGM. ** $p < 0.001$ as compared to persons who continued FSL-FGM.

Supplementary Table 5. Selected results of Diabetes Vereniging Nederland patient-reported outcome measures (DVN-PROM) questionnaire comparing persons who continued FSL-FGM and persons who had stopped FSL-FGM before the two-year follow-up period was completed

	Continued FSL-FGM (n=254)	Stopped FSL-FGM (n=79)
Hypoglycemic episodes are less severe, n (%)	208 (81.9)	9 (11.4)*
Better understanding of glucose fluctuations, n (%)	240 (94.5)	6 (7.6)*
Feeling more secure since using FSL-FGM (or stopping, respectively), n (%)	196 (77.2)	7 (8.9)*
Performing more frequent adjustments of insulin doses, n (%)	208 (81.9)	24 (30.4)*
Always measuring glucose before participating in traffic as a driver, n (%)	166 (65.4)	31 (39.2)*
Sporting and exercising more frequently, n (%)	109 (42.9)	3 (3.8)*
House mates and family members are less worried about their glucose regulation, n (%)	165 (65.0)	7 (9.0)*

Data are presented as number (%). * $p < 0.0001$ as compared to persons who continued FSL-FGM.

Supplementary Table 6. Changes in scores on the SF-12 subscales among persons who continued FSL-FGM for at least two years and persons who had stopped FSL-FGM before the two-year follow-up period was completed

	Baseline (A)		One year (B)		Two years (C)		C vs. A		C vs. B		Overall difference between groups
	Continued FSL-FGM	Stopped FSL-FGM	Continued FSL-FGM	Stopped FSL-FGM	Continued FSL-FGM	Stopped FSL-FGM	Continued FSL-FGM	Stopped FSL-FGM	Continued FSL-FGM	Stopped FSL-FGM	
Physical functioning	80.2 (77.0, 83.4)	84.2 (78.5, 89.9)	82.8 (79.6, 86.0)	83.5 (77.8, 89.3)	82.9 (79.8, 86.0)	82.3 (76.7, 87.9)	2.7 (-2.8, 8.1)	-1.9 (-11.7, 7.9)	0.1 (-5.3, 5.5)	-1.3 (-11.0, 8.5)	0.6 (-5.8, 7.0)
N	254	79	254	79	254	79					
Role physical	62.7 (60.0, 65.4)	59.8 (54.9, 64.7)	71.3 (68.5, 74.1)	62.0 (57.1, 67.0)	68.2 (65.4, 71.1)	59.5 (54.4, 64.6)	5.5 (0.7, 10.3)	-0.3 (-9.0, 8.3)	-3.1 (-8.0, 1.8)	-2.5 (-11.2, 6.2)	8.7 (2.9, 14.6)
N	254	79	254	79	254	79					
Role emotional	75.0 (72.2, 77.8)	69.0 (64.0, 74.0)	80.3 (77.7, 83.0)	67.4 (62.6, 72.2)	77.7 (75.0, 80.4)	66.5 (61.6, 71.3)	2.7 (-2.0, 7.5)	-2.5 (-11.1, 6.0)	-2.6 (-7.2, 2.0)	-0.9 (-9.3, 7.4)	11.3 (5.7, 16.8)
N	254	79	254	79	254	79					
Mental health	69.1 (66.9, 71.3)	67.9 (64.0, 71.8)	75.8 (73.8, 77.8)	73.4 (69.8, 77.0)	74.7 (72.7, 76.7)	67.4 (63.7, 71.1)	5.6 (2.0, 9.3)	-0.5 (-7.0, 6.1)	-1.1 (-4.6, 2.3)	-6.0 (-12.3, 0.2)	7.3 (3.1, 11.5)
N	254	79	254	79	254	79					
Bodily pain	83.3 (80.5, 86.0)	83.2 (78.3, 88.2)	14.2 (11.4, 16.9)	17.4 (12.5, 22.4)	85.7 (83.1, 88.3)	81.0 (76.4, 85.7)	2.5 (-2.2, 7.1)	-2.2 (-10.5, 6.1)	71.6 (66.9, 76.2)	63.6 (55.3, 71.9)	4.7 (-0.6, 10.0)
N	254	79	254	79	254	79					
General health	47.1 (44.9, 49.4)	48.1 (44.1, 52.1)	52.1 (49.8, 54.3)	50.3 (46.3, 54.3)	51.0 (48.6, 53.4)	49.1 (44.8, 53.3)	3.8 (-0.1, 7.8)	0.9 (-6.1, 8.0)	-1.1 (-5.0, 2.9)	-1.3 (-8.4, 5.8)	1.9 (-2.9, 6.8)
N	254	79	254	79	254	79					
Vitality	59.2 (56.5, 61.8)	58.5 (53.7, 63.3)	64.6 (61.9, 67.2)	63.6 (58.9, 68.3)	63.4 (60.7, 66.1)	57.3 (52.5, 62.1)	4.2 (-0.4, 8.8)	-1.3 (-9.5, 7.0)	-1.2 (-5.7, 3.4)	-6.3 (-14.5, 1.9)	6.1 (0.6, 11.6)
N	254	79	254	79	254	79					
Social functioning	72.3 (69.3, 75.4)	69.3 (63.9, 74.7)	82.1 (79.3, 84.9)	75.9 (70.9, 81.0)	79.1 (76.1, 82.1)	68.7 (63.3, 74.1)	6.8 (1.6, 12.0)	-0.6 (-10.0, 8.7)	-3.0 (-8.0, 2.1)	-7.3 (-16.3, 1.8)	10.5 (4.3, 16.7)
N	254	79	254	79	254	79					

Data are presented as mean (difference) with 95% confidence interval. SF-12^{v2}, 12-Item Short Form Health Survey^{v2}.